The combination of FDA-cleared AI software for mammography triage with a medical grade edge AI platform may allow the embedding of enhanced AI detection capability within existing mammography devices.
Could an embedded AI system within mammography devices provide enhanced images, bolster workflow efficiency, and reduce hardware upgrade costs?
MedCognetics said the combination of its CogNet AI-MT AI-powered mammography software with the medical-grade edge AI platform NVIDIA IGX Orin enables real-time processing of high-quality mammography images.
MedCognetics said the combination of CogNet AI-MT AI-powered mammography software with the medical-grade edge AI platform NVIDIA IGX Orin facilitates improved image clarity and detail as well as worklist prioritization for a significantly lower cost than hardware upgrades for mammography devices. (Images courtesy of MedCognetics.)
The combination of AI technologies reportedly facilitates improved image clarity and detail as well as worklist prioritization for a significantly lower cost than hardware upgrades for mammography devices, according to MedCognetics.
“Embedding our CogNet AI-MT software directly into mammography imaging equipment means we can enhance image quality and provide immediate cancer detection without the need for costly hardware upgrades,” said Debasish “Ron” Nag, the CEO of MedCognetics. “Using the NVIDIA IGX platform, we’re advancing medical imaging technology, making high-quality diagnostic tools more accessible to radiologists and imaging centers around the world.”
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.